NCT03010085

Brief Summary

Open versus Laparoscopic Left-sided Hepatectomy (OLLEH) trial Multi-institutional, prospective and randomized trial in patients undergoing left sided hepatectomy through laparoscopic versus open procedure. Primary endpoint: Functional recovery Secondary endpoint: Hospital duration, estimated blood loss, operation time, resection margin status, postoperative complication, mortality, liver function laboratory test, re-admission, quality of life, cosmesis, cost effectiveness

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
122

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Jan 2017

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 30, 2016

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 4, 2017

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

January 4, 2017

Status Verified

January 1, 2017

Enrollment Period

2.9 years

First QC Date

November 30, 2016

Last Update Submit

January 2, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Checklist of functional recovery (Questionnaire, liver function test of aspartate aminotransferase and alanine aminotransferase)

    Checklist of functional recovery 1. (Questionnaire) Do you want intravenous analgesics for postoperative pain ? (Yes, No) 2. (Questionnaire) Do you have trouble to ambulate by oneself ? (Yes, No) 3. (Questionnaire) Do you have trouble to digest solid meal ? (Yes, No) 4. (Questionnaire) Do you want intravenous fluid to subside your thirsty ? (Yes, No) 5. (Liver function test) Are serum aspartate aminotransferase and alanine aminotransferase increasing ? (Yes, No) * Daily check the five item above until every item is 'No' * If all of the items are 'No', the patient is regarded as a functionally recovered state.

    up to 30 days

Secondary Outcomes (9)

  • Postoperative complication

    up to 30 days

  • Mortality

    up to 30 days

  • Readmission rate

    up to 30 days

  • Hospital duration

    up to 30 days

  • Blood loss

    up to 30 days

  • +4 more secondary outcomes

Study Arms (2)

A (Open left-sided hepatectomy)

ACTIVE COMPARATOR

Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy

Procedure: Open left-sided hepatectomy

B (Laparoscopic left-sided hepatectomy)

EXPERIMENTAL

Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy

Procedure: Laparoscopic left-sided hepatectomy

Interventions

Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy

Also known as: Left-sided hepatectomy, Left lateral sectionectomy, Left hemihepatectomy
A (Open left-sided hepatectomy)

Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy

Also known as: Laparoscopic left lateral sectionectomy, Laparoscopic left hemihepatectomy
B (Laparoscopic left-sided hepatectomy)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient who underwent open or laparoscopic left-sided hepatectomy for benign or malignant neoplasm of the liver
  • Child-Pugh A without portal hypertension
  • No portosystemic shunt
  • No splenomegaly
  • Platelet count \>100,000/ul
  • Age 18 to 80
  • Eastern Cooperative Oncology Group performance status: 0 or 1
  • American society of anesthesiology class: I or II
  • Informed consent

You may not qualify if:

  • Additional intervention to the liver (Radio Frequent Ablation, Percutaneous Ethanol. Injection Therapy or others)
  • Combined hepatectomy
  • Bile duct reconstruction
  • Intrahepatic duct stone
  • Upper abdominal laparotomy history
  • Previous hepatectomy
  • Combined operation for extrahepatic disease
  • Vulnerable population (mental retardation, pregnancy)
  • Patient who participated in other clinical trial within 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ewha Womans University Mokdong Hospital

Seoul, 07985, South Korea

Location

Related Links

MeSH Terms

Conditions

Liver Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesLiver Diseases

Central Study Contacts

Seung Duk Lee, MD

CONTACT

Yunsung Seo, MS

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

November 30, 2016

First Posted

January 4, 2017

Study Start

January 1, 2017

Primary Completion

December 1, 2019

Study Completion

December 1, 2021

Last Updated

January 4, 2017

Record last verified: 2017-01

Data Sharing

IPD Sharing
Will not share

Locations